Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares are trading higher Wednesday after the company announced it received FDA ...
Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (Orbit) or bisphosphonates ...
Ultragenyx Pharmaceutical (RARE) remains a Sell after its Phase 3 OI program failed to meet primary fracture reduction ...
anthropomorphism: When humans tend to give nonhuman objects humanlike characteristics. In AI, this can include believing a ...
SELLAS Life Sciences Virtual R&D Day -- October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 ...
We recently published 10 Stocks on Fire Ahead of 2026. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the best performers on Tuesday. Ultragenyx rebounded by 15.52 percent on Tuesday to close ...
The emergence of next-generation KRAS G12C inhibitors has led Verastem Oncology to change course. | The emergence of ...
Chemoendocrine therapy shows a greater negative association with patient-reported cognitive decline than endocrine therapy ...
Ultragenyx and Mereo BioPharma hit 52-week low after disappointing results from Phase 3 studies for Osteogenesis Imperfecta ...
A research paper by scientists from Beihang University proposed a machine learning (ML)-driven cerebral blood flow (CBF) prediction model, featuring multimodal imaging data integration and an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback